Literature DB >> 11071886

Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90.

W Xu1, E Mimnaugh, M F Rosser, C Nicchitta, M Marcu, Y Yarden, L Neckers.   

Abstract

ErbB receptors are a family of ligand-activated tyrosine kinases that play a central role in proliferation, differentiation, and oncogenesis. ErbB2 is overexpressed in >25% of breast and ovarian cancers and is correlated with poor prognosis. Although ErbB2 and ErbB1 are highly homologous, they respond quite differently to geldanamycin (GA), an antibiotic that is a specific inhibitor of the chaperone protein Hsp90. Thus, although both mature and nascent ErbB2 proteins are down-regulated by GA, only nascent ErbB1 is sensitive to the drug. To reveal the underlying mechanism behind these divergent responses, we made a chimeric receptor (ErbB1/2) composed of the extracellular and transmembrane domains of ErbB1 and the intracellular domain of ErbB2. The ErbB1/2 protein is functional since its kinase activity was stimulated by epidermal growth factor. The sensitivity of ErbB1/2 to GA was similar to that of ErbB2 and unlike that of ErbB1, indicating that the intracellular domain of the chimera confers GA sensitivity. This finding also suggests that the GA sensitivity of mature ErbB2 depends on cytosolic Hsp90, rather than Grp94, a homolog of Hsp90 that is restricted to the lumen of the endoplasmic reticulum, although both chaperones bind to and are inhibited by GA. Lack of Grp94 involvement in mediating ErbB2 sensitivity to GA is further suggested by the fact that a GA derivative with low affinity for Grp94 efficiently depleted ErbB2 protein in treated cells. To localize the specific region of ErbB2 that confers GA sensitivity, we made truncated receptors with progressive deletions of the cytoplasmic domain and tested the GA sensitivity of these molecules. We found that ErbB2 constructs containing an intact kinase domain retained GA sensitivity, whereas those lacking the kinase domain (ErbB2/DK) lost responsiveness to GA completely. Hsp90 co-immunoprecipitated with all ErbB2 constructs that were sensitive to GA, but not with ErbB2/DK or ErbB1. Both tyrosine-phosphorylated and non-phosphorylated ErbB2 proteins were similarly sensitive to GA, as was a kinase-dead ErbB2 mutant. These data suggest that Hsp90 uniquely stabilizes ErbB2 via interaction with its kinase domain and that GA stimulates ErbB2 degradation secondary to disruption of ErbB2/Hsp90 association.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11071886     DOI: 10.1074/jbc.M006864200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  135 in total

1.  Β-elemene inhibits Hsp90/Raf-1 molecular complex inducing apoptosis of glioblastoma cells.

Authors:  Yong-Shun Zhao; Ting-Zhun Zhu; Yan-Wei Chen; Yi-Qun Yao; Chun-Ming Wu; Zhen-Qing Wei; Wei Wang; Ying-Hui Xu
Journal:  J Neurooncol       Date:  2011-12-11       Impact factor: 4.130

2.  Design and synthesis of Hsp90 inhibitors: exploring the SAR of Sansalvamide A derivatives.

Authors:  Robert P Sellers; Leslie D Alexander; Victoria A Johnson; Chun-Chieh Lin; Jeremiah Savage; Ricardo Corral; Jason Moss; Tim S Slugocki; Erinprit K Singh; Melinda R Davis; Suchitra Ravula; Jamie E Spicer; Jenna L Oelrich; Andrea Thornquist; Chung-Mao Pan; Shelli R McAlpine
Journal:  Bioorg Med Chem       Date:  2010-07-22       Impact factor: 3.641

3.  Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2.

Authors:  Pallav D Patel; Pengrong Yan; Paul M Seidler; Hardik J Patel; Weilin Sun; Chenghua Yang; Nanette S Que; Tony Taldone; Paola Finotti; Ralph A Stephani; Daniel T Gewirth; Gabriela Chiosis
Journal:  Nat Chem Biol       Date:  2013-09-01       Impact factor: 15.040

4.  Structure of an Hsp90-Cdc37-Cdk4 complex.

Authors:  Cara K Vaughan; Ulrich Gohlke; Frank Sobott; Valerie M Good; Maruf M U Ali; Chrisostomos Prodromou; Carol V Robinson; Helen R Saibil; Laurence H Pearl
Journal:  Mol Cell       Date:  2006-09-01       Impact factor: 17.970

5.  Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction.

Authors:  Hailin Yang; Sung-Kwon Kim; Mikyung Kim; Pedro A Reche; Tiara J Morehead; Inger K Damon; Raymond M Welsh; Ellis L Reinherz
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

Review 6.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

7.  Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu.

Authors:  Wanping Xu; Monica Marcu; Xitong Yuan; Edward Mimnaugh; Cam Patterson; Len Neckers
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-18       Impact factor: 11.205

8.  5'-N-ethylcarboxamidoadenosine is not a paralog-specific Hsp90 inhibitor.

Authors:  Shanshan Liu; Timothy O Street
Journal:  Protein Sci       Date:  2016-10-04       Impact factor: 6.725

9.  Geldanamycin selectively targets the nascent form of ERBB3 for degradation.

Authors:  Candice S Gerbin; Ralf Landgraf
Journal:  Cell Stress Chaperones       Date:  2010-01-19       Impact factor: 3.667

10.  Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cells.

Authors:  Cinzia Giordano; Donatella Vizza; Salvatore Panza; Ines Barone; Daniela Bonofiglio; Marilena Lanzino; Diego Sisci; Francesca De Amicis; Suzanne A W Fuqua; Stefania Catalano; Sebastiano Andò
Journal:  Mol Oncol       Date:  2012-11-23       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.